Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1544141 | 0.95 | LMNA (0.58) | MAPTLMNAHTTKCNH2DRD2 | |
| SCHEMBL1544377 | 0.94 | MAPT (0.52) | MAPTLMNAHTTKCNH2DRD2 | |
| SCHEMBL1543946 | 0.93 | CYP3A4 (0.57) | MAPTLMNAHTTKCNH2DRD2 | |
| SCHEMBL1544330 | 0.92 | MAPT (0.50) | MAPTLMNAHTTKCNH2DRD2 | |
| SCHEMBL1544120 | 0.92 | MAPT (0.50) | MAPTLMNAHTTKCNH2DRD2 | |
| SCHEMBL1544219 | 0.92 | MAPT (0.53) | MAPTLMNAHTTKCNH2DRD2 | |
| SCHEMBL1543710 | 0.92 | LMNA (0.51) | MAPTLMNAHTTKCNH2DRD2 | |
| SCHEMBL1544097 | 0.92 | MAPT (0.64) | MAPTLMNAHTTKCNH2DRD2 | |
| SCHEMBL1544357 | 0.91 | LMNA (0.49) | MAPTLMNAHTTKCNH2DRD2 | |
| SCHEMBL1544616 | 0.91 | MAPT (0.48) | MAPTLMNAHTTKCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| WO-2005077345-A1 | COMPOUNDS FOR THE TREATMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE | ASTRAZENECA AB (SE) | 2005-08-25 | — | — | WO | claimed |
| EP-1529045-A2 | NEW COMPOUNDS | Astra Zeneca AB (SE) | 2005-05-11 | — | — | EP | claimed |
| US-20050049306-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | HARPER DAVID SCOTT (US) | 2005-03-03 | — | — | US | claimed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | claimed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | claimed |
| US-20040010046-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | MCNEIL-PPC, INC | 2004-01-15 | — | — | US | claimed |
| US-20020110530-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | HARPER DAVID SCOTT (US) | 2002-08-15 | — | — | US | claimed |
| EP-2311830-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-1723144-B1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7456200-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-11-25 | — | — | US | disclosed |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| EP-1409443-A2 | NON-HALOGENATED NAPHTHOL COMPOUNDS, ANTIMICROBIAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | WARNER-LAMBERT COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
| US-20040010046-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | MCNEIL-PPC, INC | 2004-01-15 | — | — | US | disclosed |
| US-20020110530-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | HARPER DAVID SCOTT (US) | 2002-08-15 | — | — | US | disclosed |
| WO-2002050001-A2 | NON-HALOGENATED NAPHTHOL COMPOUNDS AND ANTIMICROBIAL COMPOSITIONS CONTAINING THE SAME | WARNER-LAMBERT COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152699-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | MAPT 1620/4885LMNA 900/4885HTT 1365/4885 |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | MAPT 780/4885LMNA 4509/4885HTT 350/4885 |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | GRM5, GRIK5, GRM1 | MAPT 1167/4885LMNA 4511/4885HTT 780/4885 |
| US-20050049306-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | NPM1, NOC2L, NAF1 | MAPT 3735/4885LMNA 1768/4885HTT 1677/4885 |
| US-20040010046-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | NPM1, NOC2L, NAF1 | MAPT 3735/4885LMNA 1768/4885HTT 1677/4885 |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | MAPT 780/4885LMNA 4509/4885HTT 350/4885 |
| US-20020110530-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | NPM1, NOC2L, NAF1 | MAPT 3735/4885LMNA 1768/4885HTT 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.